Inogen Inc Dossier - Source-backed chat

Inogen Inc

INGNNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.39

Intrinsic Value $8.68median of 2 methodsbased on filings through 30 Jun 2026

Market Price $5.98Price as of 1 Oct 2026

UndervaluedIntrinsic value is 45% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $158.7M

Enterprise Value $71.4M

Shares Outstanding 27.7M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Inogen is successfully transitioning from a single-product portable oxygen concentrator (POC) company into a diversified respiratory care platform. After achieving positive Adjusted EBITDA in 2025 for the first time since 2021, the company is well-positioned to leverage its multi-product portfolio—spanning oxygen therapy, sleep therapy, airway clearance, and digital health—to drive sustainable growth. Backed by a robust balance sheet with $111.5 million in cash and no debt, alongside a newly authorized $30 million share repurchase program, Inogen offers an attractive risk-reward profile as operating leverage begins to flow to the bottom line.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$12.67

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$8.0010%

Domestic rental revenue declines accelerate faster than international sales can offset, or execution delays in sleep therapy and airway clearance products stall the diversification strategy. Increased R&D and commercial investments pressure margins, delaying the path to sustained GAAP profitability.

Base CaseCentral scenario

$12.0060%

Inogen delivers on its full-year 2026 revenue guidance of $366 million to $373 million (representing ~6% growth at the midpoint) and continues to show positive Adjusted EBITDA improvement. International sales remain a key growth driver, while domestic channels stabilize as new product rollouts gain traction.

Bull CaseUpside scenario

$14.0030%

Rapid adoption of new products (Voxi 5, Simeox, and Aurora CPAP masks) combined with strong international POC sales expansion drives revenue growth above the high end of guidance. Operating leverage kicks in faster than expected, leading to double-digit Adjusted EBITDA margins ahead of the 3-to-5-year target timeline.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Successful turnaround with a return to positive Adjusted EBITDA of $2.7 million in FY 2025.
Strong balance sheet with $111.5 million in cash and cash equivalents and zero debt as of Q1 2026.
Product portfolio diversification (Voxi 5, Simeox, Aurora CPAP masks) significantly expands the addressable market beyond traditional POCs.
Active capital allocation strategy supported by a $30 million share repurchase program for 2026-2027.

Key Investment Risks

Ongoing headwinds in U.S. rentals due to reimbursement mix and declining patients on service.
Execution risk associated with entering competitive adjacent markets like sleep therapy (CPAP masks).
Short-term margin pressure from elevated R&D, clinical trials, and commercial investments.

Thesis Invalidation Triggers

Failure to achieve positive Adjusted EBITDA improvement for the full year 2026.
A drop in total cash and cash equivalents below $90 million due to excessive cash burn.
A material decline in international POC sales growth, which currently acts as the primary revenue driver.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.